X4 Pharmaceuticals (XFOR) News Today $2.71 -0.21 (-7.19%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period X4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA CongressMay 16, 2025 | nasdaq.comX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14, 2025 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings ResultsX4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($4.13) by $4.17. The company had revenue of $28.81 million during the quarter, compared to the consensus estimate of $7.03 million.May 5, 2025 | marketbeat.comX4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright upped their target price on X4 Pharmaceuticals from $1.50 to $7.00 and gave the stock a "buy" rating in a research note on Friday.May 4, 2025 | marketbeat.comX4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 2, 2025 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4.9% - Time to Sell?X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Down 4.9% - What's Next?May 1, 2025 | marketbeat.comX4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | finance.yahoo.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | globenewswire.comX4 Pharmaceuticals Q1 2025 Earnings PreviewApril 30, 2025 | msn.comX4 Pharmaceuticals Analyst RatingsApril 30, 2025 | benzinga.comEarnings Preview For X4 PharmaceuticalsApril 30, 2025 | benzinga.comX4 Pharmaceuticals (NASDAQ:XFOR) Sets New 1-Year Low - Here's WhyX4 Pharmaceuticals (NASDAQ:XFOR) Hits New 1-Year Low - Here's What HappenedApril 30, 2025 | marketbeat.comX4 Pharmaceuticals To Implement 1-for-30 Reverse Stock Split On April 28April 26, 2025 | nasdaq.comX4 Pharmaceuticals trading halted, news pendingApril 26, 2025 | markets.businessinsider.comX4 Pharmaceuticals announces 1-for-30 reverse stock splitApril 26, 2025 | markets.businessinsider.comX4 Pharmaceuticals to conduct reverse stock splitApril 24, 2025 | msn.comX4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025April 24, 2025 | globenewswire.comX4 Pharmaceuticals Announces Reverse Stock SplitApril 24, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 23, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comXFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25…March 27, 2025 | finance.yahoo.comBreaking Down X4 Pharmaceuticals: 4 Analysts Share Their ViewsMarch 27, 2025 | benzinga.comX4 Pharmaceuticals reports Q4 EPS (20c) vs. (10c) last yearMarch 26, 2025 | markets.businessinsider.comX4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Misses Estimates By $0.03 EPSX4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.03).March 26, 2025 | marketbeat.comX4 Pharmaceuticals outlines expected 2026 Phase 3 trial data release for mavorixaforMarch 25, 2025 | msn.comX4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | seekingalpha.comX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comX4 Pharmaceuticals Q4 2024 Earnings PreviewMarch 24, 2025 | msn.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest UpdateX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 9,480,000 shares, a decrease of 14.3% from the February 13th total of 11,060,000 shares. Currently, 5.7% of the shares of the company are sold short. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is currently 2.3 days.March 19, 2025 | marketbeat.comX4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on TuesdayX4 Pharmaceuticals (NASDAQ:XFOR) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=674044)March 18, 2025 | marketbeat.comX4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025March 11, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Down 33.4% in FebruaryX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 11,060,000 shares, a decline of 33.4% from the January 31st total of 16,610,000 shares. Based on an average daily volume of 4,110,000 shares, the short-interest ratio is presently 2.7 days.March 2, 2025 | marketbeat.comX4 and taiba rare announce distribution agreement for XolremdiFebruary 19, 2025 | markets.businessinsider.comX4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East CountriesFebruary 19, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 22.6% in JanuaryX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 16,610,000 shares, an increase of 22.6% from the January 15th total of 13,550,000 shares. Based on an average trading volume of 5,310,000 shares, the days-to-cover ratio is presently 3.1 days.February 16, 2025 | marketbeat.comX4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stockFebruary 14, 2025 | msn.comHC Wainwright Cuts Earnings Estimates for X4 PharmaceuticalsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Investment analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of X4 Pharmaceuticals in a report released on Friday, February 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post eaFebruary 10, 2025 | marketbeat.comXFOR FY2027 EPS Reduced by Brookline Capital ManagementX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Capital Management dropped their FY2027 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a research report issued on Thursday, February 6th. Brookline Capital Management analyst L.February 10, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for X4 Pharmaceuticals (NASDAQ:XFOR)HC Wainwright reissued a "buy" rating and set a $1.50 price objective on shares of X4 Pharmaceuticals in a research report on Friday.February 7, 2025 | marketbeat.comOne year after drug approval, X4 Pharmaceuticals cuts staffFebruary 6, 2025 | bizjournals.comX4 Pharmaceuticals announces strategic restructuring, reduces headcount by 30%February 6, 2025 | markets.businessinsider.comX4 Pharmaceuticals To Axe 30% Of Overall Workforce, Stock Falls In Pre-MarketFebruary 6, 2025 | markets.businessinsider.comX4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic NeutropeniaFebruary 6, 2025 | globenewswire.comX4 said to see takeover approach from Italy’s Cheisi, Street Insider reportsJanuary 30, 2025 | markets.businessinsider.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells $10,016.10 in StockJanuary 28, 2025 | insidertrades.comX4 Pharmaceuticals' chief medical officer sells $5,284 in stockJanuary 28, 2025 | msn.comInsider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells 22,258 Shares of StockX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) COO Mary Dibiase sold 22,258 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $10,016.10. Following the completion of the sale, the chief operating officer now owns 490,980 shares in the company, valued at approximately $220,941. The trade was a 4.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.January 27, 2025 | marketbeat.comMark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) StockX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) insider Mark Baldry sold 29,159 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $13,121.55. Following the completion of the sale, the insider now owns 94,123 shares in the company, valued at approximately $42,355.35. This trade represents a 23.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.January 27, 2025 | marketbeat.com Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Media Mentions By Week XFOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XFOR News Sentiment▼0.690.65▲Average Medical News Sentiment XFOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XFOR Articles This Week▼32▲XFOR Articles Average Week Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BYSI News Today PDSB News Today SKYE News Today CTOR News Today ABOS News Today XCUR News Today APLT News Today MGX News Today CNTX News Today ACHL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XFOR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
